Jakob Fink-Lamotte1,2*†
Sebastian Wehle3Frederica Brinkmann1Marie Pelzer1Cornelia Exner2
Christian Stierle4,5- 1Clinical Psychology, University of Potsdam, Potsdam, Germany
- 2Clinical Psychology and Psychotherapy, University of Leipzig, Leipzig, Germany
- 3Experimental Psychology and Methods, University of Leipzig, Leipzig, Germany
- 4School of Psychology, Fresenius Hochschule für Wirtschaft und Medien, Hamburg, Germany
- 5Health Psychology and Paedagogy, Riga Stradins University, Riga, Latvia
Introduction: Skin diseases are among the most common diseases worldwide and can cause severe psychological and social impairments. Negative self-directed emotions like shame and disgust may be important in the development and progression of these diseases, and thus, patients may benefit from psychotherapeutic approaches targeting shame and self-disgust. The first aim of this systematic review is to investigate the existing literature regarding shame and disgust as psychological correlates of inflammatory skin diseases. The second aim is to review the existing literature concerning the evidence of the efficacy of mindfulness-based and compassion-based therapy for alleviating shame and self-disgust in the context of skin diseases.
Methods: Therefore, we carried out a systematic literature review via the databases PubMed, Web of Science and PSYINDEX.
Results: 46 manuscripts were included in this review. Research shows that acne vulgaris, psoriasis, and atopic eczema are accompanied by a severe psychosocial burden, shame, and self-disgust, often due to highly visible skin lesions in affected patients. The use of mindfulness-based and compassion-based approaches is already being studied to address the experiences of shame and disgust due to these diseases, and initial promising results indicate that they can be considered beneficial in the holistic therapy of skin diseases.
Discussion: This systematic review shows that skin disorders have a significant psychosocial impact, leading to shame and self-disgust, especially due to the manifestation of visible skin lesions in affected patients. Mindfulness- and compassion-based approaches are currently being studied as potential treatments for the psychosocial impacts of skin diseases, and show promising results in addressing affected patients’ psychological burden.
Highlights
1. Patients with the three included inflammatory skin diseases are burdened by shame and self-disgust, often related to experiences and fear of social rejection
2. Shame and self-disgust may lead to social withdrawal, affecting life quality, treatment compliance and symptom progression, but causal evidence is lacking
3. Mindfulness- and compassion-based approaches are promising in alleviating shame and self-disgust
1 Introduction
Skin diseases, including fungal skin diseases, other skin and subcutaneous conditions, and acne, ranked among the top ten most common diseases worldwide in 2010 (1). In a study involving 90,880 employees conducted from 2004 to 2009, 3.9% had acne vulgaris, 2% had psoriasis, and 1.3% had atopic eczema (2), making these inflammatory dermatological conditions three of the most prevalent skin diseases. A British report revealed that 14% of surveyed dermatological patients reported that their skin conditions were exacerbated by psychological factors, while 85% noted that the interference with their social relationships was the most distressing aspect of their illness (3). Importantly, the study highlighted a notably higher suicide rate among patients with inflammatory skin diseases, surpassing that in the general population (4). 17% of surveyed dermatological patients required psychotherapeutic treatment (3).
1.1 The emotional consequences of skin diseases: disgust and shame
Rook and Wilkinson (5) already argued in the late 1970s that “[.] the role of emotional factors on diseases of the skin is of such significance that, if they are ignored, the effective management of at least 40% of the patients attending departments of dermatology is impossible” (6). From an evolutionary standpoint, Kellett and Gilbert (7) center their focus on self-related negative emotions like shame and disgust. Their bio-psycho-social model, as depicted in Figure 1, serves as the foundation for this systematic review. They argue that acne’s development and progression stem from a combination of genetic factors and the stressors of puberty. The authors propose that when acne symptoms become prominent, individuals experience negative thoughts and emotions, especially related to the self, along with social challenges. These internal struggles and interpersonal issues adversely affect mood, behavior, and immune system function, further impacting stress levels, acne symptoms, and the emergence of additional psychological problems. The bio-psycho-social model of acne (Figure 1) can also be applied to the clinical presentation of psoriasis and atopic eczema, as all three conditions involve inflammatory skin issues that can negatively impact social life, emotional and psychological wellbeing. The connection of stress, social factors, and negative emotions with skin diseases is supported by evidence (6, 8), while a systematic review on shame and self-disgust in skin diseases is lacking.
Figure 1. The adapted biopsychosocial model of skin disease development and progression, adopted from Kellett and Gilbert (7).
The basic human emotion of disgust is described as a form of rejection that arises from the need to distance oneself from a contaminated stimulus and is characterized by feelings of nausea and revulsion (9). Disgust is considered to be an adaptive emotion, which is an evolved response to objects in the environment that pose a (perceived) threat in terms of contagion through infectious diseases (10). Self-disgust describes feelings of reluctance and repulsion directed against specific aspects of one’s own person (11), whereas (general) shame is believed to be an incapacitating emotion that is accompanied by the feeling of being small, inferior, and of “shrinking,” whereby the self, as a whole, is devalued and considered to be inadequate, incompetent, and worthless (12). Shame is viewed from a more differentiated perspective, and a distinction is made between external and internal shame. External shame refers to the experience of the self as existing negatively in the minds of others, and thus as having visible deficits, failures, or mistakes (13). Internal shame, by contrast, is linked to the inner dynamics of the self and one’s judgements and evaluations (13). The distinction between shame and embarrassment is debated, with researchers suggesting distinctions in terms of intensity of affect, severity of transgression or patterns of attribution to the presented (embarrassment) vs. the core (shame) self (14). However, despite empirical evidence for their distinctness (15, 16), shame and embarrassment are not always distinguished unequivocally, and, as a result, when many researchers speak of embarrassment, it is more accurate to think of shame (17).
Shame in the context of skin disease may arise from the experience of stigma (18). Stigma refers both to social reactions to attributes seen as degrading or devaluating (e.g., blemished skin), and to the internalization of such devaluation, termed self-stigma (19). Self-stigma and shame are thus closely related, both involving the devaluation of self, and are sometimes used interchangeably (20, 21). The impacts of stigma in skin diseases have been reviewed elsewhere (18, 22), whereas shame and self-stigma have not been investigated separately in skin diseases.
Kellett and Gilbert (7) also explore the impact of social difficulties and the importance of attractiveness on body shame reactions. In the context of body shame reactions, Gilbert (13) defines it as shame related to one’s own body, particularly concerning skin. In society, clear skin is idealized as a feature of “desirable individuals” (p. 10), and blemished or diseased skin can be perceived as a sign of poor overall health. Consequently, those affected may fear eliciting negative emotions like fear, anger, or disgust in others, potentially diminishing their desirability in various aspects, notably sexually.
Despite the importance of shame and self-disgust for the connections between social challenges, wellbeing, and symptom exacerbation posited in the bio-psycho-social model, the influence of these emotions on the wellbeing and treatment of individuals with skin disorders has received limited attention. Thus, this paper’s primary goal is to review existing literature, specifically focusing on the evidence supporting shame and self-disgust as psychological consequences and potential enhancers of inflammatory skin diseases. Reviewing the evidence will help identify gaps in the literature and guide further research into the psychological burdens and treatment of patients with skin diseases.
1.2 Psychotherapy for dermatological diseases
In various studies with patients suffering from atopic eczema or psoriasis vulgaris, the beneficial effects of combined dermatological and psychosocial interventions on the improvement of the skin condition, reduction of scratching frequency, and psychosocial parameters have been demonstrated (23). Good results are also obtained in approaches like relaxation, breathing, and art therapy, or psychodynamic catathymic image perception (24). Cognitive therapies focus on the dysfunctional appraisal of stressful events (25). Most approaches, however, lack a focus on challenging emotions such as shame and self-disgust (23). Modern psychotherapy has increasingly embraced mindfulness techniques, derived from Buddhism, such as mindfulness-based stress reduction (MBSR) and mindfulness-based therapies (MBT). These approaches adapt mindfulness from Buddhism to promote acceptance of current situations, reduce mental distress, and enhance overall psychological wellbeing. Stress-related skin conditions can benefit from these mindfulness practices, as they help reduce the mental noise and foster wisdom, ultimately increasing tolerance to stress and improving skin health (26). Additionally, self-compassion, a key concept in compassion-focused therapy (CFT), involves viewing oneself kindly and empathetically during challenging times, recognizing the universality of suffering, and mindfully accepting it (27). Unlike shame, which entails self-devaluation and a harsh self-critical relationship, self-compassion nurtures a loving, understanding, and forgiving self-relationship (28). By promoting better self-regulation and motives to alleviate suffering, mindfulness and self-compassion interventions can effectively address pathological shame and self-disgust in the context of skin diseases. As such, the second objective of this study is to review existing literature on the scientific evidence for using compassion-based or mindfulness-based therapies to address self-disgust and shame in individuals with skin diseases.
2 Materials and methods
We chose a methodological approach based on the PRISMA statement (29) for study selection, systematic search and data synthesis. Ethics approval is not required for this type of research at our institution.
2.1 Study selection
Studies were selected using the inclusion and exclusion criteria defined prior to the literature search. Inclusion criterion 1 included studies investigating emotions of shame (or self-stigmatization or embarrassment) or self-disgust or experience of disgust in the context of (psycho-)dermatological diseases (psoriasis, acne, atopic eczema). Criterion 2 included studies investigating mindfulness-based or compassion-focused-therapy regarding the emotions shame or self-disgust in patients with dermatological diseases (psoriasis, acne, atopic eczema). We did not define any excluding design parameters and only included studies focusing on adult populations (≥ 18 year).
Furthermore, we excluded pharmaceutical studies, quality assessments of clinical instruments or questionnaires, studies linking other types of emotions (e.g., nausea or anxiety) to skin diseases, and studies focusing on other types of dermatological diseases (e.g., sexually infectious diseases or skin picking). Additionally, as the effects of mindfulness interventions for improving quality of life (30) and experience of stigma in patients with skin diseases (18, 22) have recently been reviewed, studies with a primary focus on quality of life or stigmatization (without differentiating aspects of stigma) in the context of dermatological diseases were excluded. Studies examining mindfulness or self-compassion as traits or variables in therapy research were also excluded, a comprehensive review for the context of dermatological diseases was recently published (31). Studies examining compassion or mindfulness strategies outside of the context of dermatological diseases, or emotions of shame or disgust, were also excluded.
2.2 Search strategy
Based on our criteria, search terms were defined and combined logically to build a search operator. We used wildcards to include multiple concrete forms of the same word-stems: [(skin disease) OR (skin condition*) OR (disease risk) OR (dermatolog*) OR (acne) OR (eczema) OR (psoriasis)] AND {(shame) OR (disgust) OR (mindfulness) OR (compassion) OR (self-compassion) OR (bodily suffering) OR [(emotion*) AND (psycho*) AND (psychotherap*)] OR [(emotion*) AND (psycho*) AND (dermatolog*)]}. PubMed provides an option to add a NOT-operator. This was added for the following terms: NOT sexual abuse[Title/Abstract] NOT childhood[Title/Abstract] NOT dement*[Title/Abstract] NOT HIV/AIDS[Title/Abstract] NOT HIV[Title/Abstract] NOT breast cancer[Title]. The search results were combined using reference management software.
The systematic search was conducted in January 2022 via the databases PubMed, Web of Science and PSYINDEX and yielded N = 6,505 studies (n = 2,097 Doublettes). One study [(32), retrieved via Google Scholar] was published later in 2022 and was subsequently added to the search results. One relevant study (32) was excluded by our search operator because it contained the word “childhood” in the abstract.
2.3 Data synthesis
The screening of the results was conducted between January and September 2022 (see Figure 2 for the PRISMA flow chart). A random selection of 496 studies was screened independently by all three reviewers based on the inclusion/exclusion criteria outlined above. The remaining studies were split equally and randomly between the three reviewers and screened accordingly. The set of randomly selected studies was used to estimate the inter-rater reliability. Although all three reviewers agreed concerning a binary decision (in-/exclusion) for 96.6% of the studies, the inter-rater reliability of the study selection was weak (kfleiss = 0.359). Disagreements regarding the selection existed in the case of n = 17 studies and were discussed by all co-authors. Further inspection showed that two studies with relation to the quality of life also contained aspects of the emotion of embarrassment (33, 34) and were thus considered relevant. Furthermore, the inclusion and exclusion criteria related to social anxiety [included; (35, 36)], feelings of stigma [included; (35, 37, 38)], and skin picking [excluded; (39)] were interpreted differently by the reviewers. After discussing and resolving the disagreements, the agreement of study selection was 97.5% with substantial inter-rater reliability (kfleiss = 0.659). One study (40) was falsely excluded in the screening and included in the review process thanks to one reviewer’s comment. All studies for which reviewers were not able to resolve their disagreements were included in the next step of retrieving the full manuscripts.
Figure 2. PRISMA flow chart. 1One Author reported a google-scholar-based recommendation for a study that had not been in the original screening but passed inclusion criteria. Reviewers recommended another two relevant studies. *Consider, if feasible to do so, reporting the number of records identified from each database or register searched (rather than the total number across all databases/registers). **If automation tools were used, indicate how many records were excluded by a human and how many were excluded by automation tools. *** by automation tool + by human during screening [From (29)]. For more information, visit: http://www.prisma-statement.org.
The full manuscripts of the remaining studies were subsequently retrieved. Studies were excluded if the full text was not available (n = 11), not written in English or German (n = 3), had a focus on skin disease or emotion that did not fit the inclusion criteria (n = 36), did not include an adult sample (n = 2), or investigated mindfulness and self-compassion as traits or not in relation to disgust or shame (n = 21). The main results across each group of studies were then summarized for a synthesis of the main outcomes.
2.4 Risk of bias assessment
The risk of bias was assessed independently using the NHLBI quality assessment tool (41). The tool consists of a catalog of questions that ask key questions about the internal validity of the respective study. There is a separate, suitable list of questions for each study type (controlled intervention studies, systematic reviews and Meta-Analyses, Observational Cohort, Case-Control Studies, etc.). Each point is queried with yes/no questions (unsuitable or non-answerable questions are answered with NA or “not reported”) and categorized as “good,” “fair” or “poor” (no quantification) according to predefined rules. Five independent reviewers rated the studies according to the applicable criteria. The detailed results of the risk of bias assessment can be found in the Supplementary Table 1. Systematic Reviews and Meta-Analyses often exhibited poor quality, raising concerns about the reliability of their findings. Controlled Intervention Studies, on the other hand, presented a heterogeneous picture ranging from poor to good quality, indicating the need for more standardized methodologies. Most studies fell within the category of Observational Cohort and Cross-Sectional Studies. These studies demonstrated varying degrees of quality, generally falling within the fair to good range. Additionally, a selection of qualitative studies was also included in the analysis contributing to the diversity of the evidence base. Based on the COREQ-Assessment (42) they showed fair to good quality.
3 Results
3.1 Shame, embarrassment, and self-stigma in dermatological diseases
Most of the literature that has examined shame, embarrassment, and self-stigma in dermatological conditions and that was included in the review comprised studies that examined patients with psoriasis. A total of 33 out of 46 included studies (72%) focussed exclusively or i.a., on psoriasis, while fewer studies focussing on acne (9 studies, 19%) or atopic eczema (4 studies 8.7%) were found.
Several questionnaire studies show that people with skin diseases displayed high levels of shame (17, 43–46), albeit not general shame (47) [see review by (48)]; skin shame (48); social shame (49). In a cross-sectional study with 166 psoriasis patients, Jankowiak et al. (50) showed that higher levels of shame were especially found in cases with visible skin lesions [see review by (51)] and that older patients reported less shame.
In addition, questionnaire studies found high levels of embarrassment (17, 33, 43, 45, 46, 52–55) associated with high self-consciousness about the skin disease (17, 56, 57), as well as high levels of self-stigma (17, 34, 58) in people with skin diseases. Again, visible lesions (e.g., scars) were associated with more embarrassment (59), and in psoriasis patients, this was even more acute than in people suffering from atopic eczema (60). Additionally, in a meta-analysis of ten qualitative studies of people with various dermatological conditions, emotional experience with embarrassment and shame emerged as one of the main themes (61). In one study, shame experience was also highlighted as the unifying factor between psoriasis and acne inversa patients in particular (62).
Lahousen et al. (32) found that patients with psoriasis reported significantly higher levels of skin-related shame and disgust than healthy controls, as well as more negative appraisals of self-touching and parental touching. Interestingly, severity of skin condition was unrelated to shame and disgust. A qualitative study also found that people suffering from skin diseases had an impaired self-image and low self-esteem (17, 63, 64). In a study on sexual problems in psoriasis, the majority of men reported feeling embarrassed and less attractive due to skin lesions, and at least occasionally ashamed with sexual partners (65). Psoriasis patients often cited feelings of being stared at, and others’ erroneous beliefs that the disease was contagious, as stressors (65, 66). These feelings may cause avoidant behavior, thus perpetuating social exclusion and explaining the link between shame, stigmatization, and depression as well as lower quality of life (67).
The study by Ginsburg and Link (37) showed that the fear of social exclusion harbored by psoriasis patients is not completely unjustified: 19% of patients experienced episodes of gross rejection as a result of their psoriasis. These experiences were accompanied by feelings of stigmatization. Magin et al. (68) also found embarrassment and low self-esteem as a result of teasing and bullying in people with dermatological conditions while Schielein et al. (69) showed that the main reason affected patients avoided sexual activity was shame and fear of rejection [see also (70)]. Since these feelings are fundamentally associated with social withdrawal and depression, Vladut and Kállay (71) call for multidisciplinary treatment in their review.
In connection with psoriasis, Ginsburg and Link (38) worked out six dimensions of self-stigma via a questionnaire study: the anticipation of rejection, a feeling of being flawed, sensitivity to others’ attitudes, guilt and shame, secretiveness, and positive attitudes. The authors suggested that a high experience of stigma might be associated with increased non-compliance with treatment and thus symptom exacerbation.
In a study by George et al. (72), what patients found helpful in dealing with the fear of social exclusion was active listening, shared decision-making, and communication of hope.
3.2 Self-disgust and experience of disgust in dermatological diseases
The state of research on disgust in dermatological diseases is considerably less comprehensive than that on shame and embarrassment. Mento et al. (73) also came to this conclusion in a literature review, according to which anger and disgust are neglected in studies. In a qualitative study, Wahl et al. (74) show that patients with psoriasis describe their bodies (especially in the case of visible skin rashes) as “offensive” and regard themselves as “unclean, infectious, disgusting, leprous, ugly, unattractive, strange, big, or different.” [see also (67)]. In an ethnographic qualitative study in different countries, dermatological patients described themselves with disgust and self-loathing (75).
In a questionnaire study, over 60% of patients with psoriasis reported experiencing strong self-disgust (76), and the findings showed that sex, age, depression, and perceived stigmatization were predictors of self-disgust whereby the relationship between stigmatization and depression was mediated by self-disgust. Moreover, there is evidence that dermatological patients experience disgust in others differently from skin-healthy people. In an approach-avoidance task, patients with psoriasis and their significant others more strongly avoided faces displaying disgust, but not other emotions, compared to controls (40). In an fMRI study by Kleyn et al. (77), psoriasis patients showed a reduced ability to recall faces with disgust reactions compared to controls. The authors concluded that this related to learned coping mechanisms to protect themselves from the reaction of disgust in others.
3.3 Psychotherapy for dermatological diseases: compassion-based-therapeutic approaches
Although few studies to date have examined the effects of compassion-focused therapy on shame or disgust in skin conditions, empirical evidence supports the potential of CFT for reducing shame and enhancing treatment for patients with skin diseases. In a two-week randomized controlled trial (RCT) on 75 patients with facial acne who experienced skin-related distress and varying levels of depression, Kelly et al. (78) found that two compassion-focused interventions significantly reduced shame, as well as skin discomfort and depression, in comparison to a passive control. More mixed results were found in a four-week compassion focused self-help program (79). In this single-arm feasibility study with a small sample, two patients with initially high levels of shame and self-criticism reported significant reductions of shame and self-criticism at the end of the program, while two patients with relatively lower baseline levels experienced significantly increased levels of shame following the intervention (79). Thus, the limited evidence mostly supports the potential of CFT as an approach for individuals with skin diseases, particularly in reducing shame, self-criticism, and psychological distress.
3.4 Psychotherapy for dermatological diseases: mindfulness-based therapeutic approaches
For the effects of mindfulness-based approaches on shame and disgust in the context of skin disease, our search yielded only one study comparing MBT against CFT. In a feasibility RCT, Muftin et al. (80) tested a mindfulness self-help online program against a CFT program in 130 patients with psoriasis. Results showed that both four-week programs were acceptable and helpful in reducing shame and improving quality of life, suggesting that MBT may have comparable potential to CFT in alleviating shame and distress in patients with skin conditions.
4 Discussion
The primary goal of this systematic review was to search for evidence supporting that shame and self-disgust are psychological correlates of inflammatory skin diseases. The results provide strong evidence for shame, embarrassment, and self-stigma as significant aspects in dermatological conditions, particularly in individuals with psoriasis. In this line, patients often suffer from high emotional stress and social exclusion. Visible skin lesions increase the experience of shame, although older patients are often less affected. Shame and self-stigmatization do not necessarily correlate with the severity of the disease, but rather with the awareness of the skin problems and the social reactions to them. Patients report bullying, social exclusion, and misunderstandings about the degree of infection of the disease, which leads to social withdrawal and increased emotional distress. Sexual problems are also common and are associated with reduced self-esteem and shame. Results indicate that shame may contribute to symptom exacerbation via withdrawal and treatment non-compliance, though causal evidence is lacking.
The evidence found on disgust as a concomitant of dermatological diseases is less extensive than on shame. The results indicate, however, that self-disgust is an emotional response associated with dermatologic diseases, particularly in relation to visible skin rashes.
The second objective of the systematic review was to investigate the evidence for using compassion-based or mindfulness-based therapies to address self-disgust and shame in individuals with skin diseases. However, only three studies were found in total. The results on the effect of CFT-based therapy on shame and disgust in skin diseases are limited, but somewhat promising. At least there are already two RCT-studies that show that these interventions can reduce shame and skin discomfort in people with skin diseases.
The results show that further exploration of self-disgust and perceived disgust in dermatology is needed to better understand its impact on the psychological wellbeing of patients and to develop effective interventions to address this aspect of the patient experience. The relation of shame and self-disgust with fear and experience of social rejection, and the link with treatment non-compliance, support the assumption of the bio-psycho-social model that negative self-directed emotions increase stress and, as a result, skin disease symptoms. Additionally, a mediating role of shame and disgust in the links between skin disease and depression or lower quality of life indicates that negative emotions increase patients’ psychological burdens and may be associated with less effective coping. Longitudinal studies are necessary to test the causal role of shame and disgust in disease progression. Further studies should also focus strongly on the initial promising effects of CFT and MBT on shame and disgust in skin conditions.
While this systematic review provides valuable insights, several limitations should be considered. First, the overall quality of the included studies was moderate, with a particularly high risk of bias in many of the controlled intervention studies. Second, comparability across studies was limited due to substantial heterogeneity in both measurement instruments and the use of core constructs. As shown in Table 1, similar constructs such as “stigma,” “self-stigma,” and “self-disgust” were operationalized using more than 19 different instruments, reflecting inconsistent conceptualization across studies. Third, the number of intervention studies, especially randomized controlled trials, was low, which restricts the strength of conclusions regarding treatment effectiveness. Lastly, the wide publication span of the included studies (1982–2022) may have introduced cohort effects, potentially contributing to variability in findings.
Table 1. Details of included studies.
In conclusion, the findings of this review align with the adapted biopsychosocial model of skin disease progression. Patients with the three included inflammatory skin diseases are burdened by shame and self-disgust —central emotional responses to negative self-appraisal and social rejection—which are often related to experiences and fear of social rejection. These processes mirror the model’s pathways from skin conditions to negative self-related emotions, social difficulties, and increased arousal, though causal evidence is lacking. Mindfulness- and compassion-based approaches appear promising in addressing these shame and self-disgust and improving patient outcomes.
Data availability statement
The original contributions presented in this study are included in this article/Supplementary material, further inquiries can be directed to the corresponding author.
Author contributions
JF-L: Conceptualization, Data curation, Investigation, Project administration, Resources, Supervision, Validation, Writing – original draft, Writing – review and editing. SW: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Software, Validation, Visualization, Writing – original draft, Writing – review and editing. FB: Writing – review and editing. MP: Writing – review and editing. CE: Conceptualization, Data curation, Investigation, Validation, Writing – review and editing. CS: Conceptualization, Data curation, Investigation, Supervision, Validation, Writing – review and editing.
Funding
The authors declare that no financial support was received for the research and/or publication of this article.
Acknowledgments
We thank Pauline Platter for her help in the first research attempts to conduct the review.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The authors declare that no Generative AI was used in the creation of this manuscript.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2025.1620940/full#supplementary-material
References
1. Hay R, Johns N, Williams H, Bolliger I, Dellavalle R, Margolis D, et al. The global burden of skin disease in 2010: An analysis of the prevalence and impact of skin conditions. J Invest Dermatol. (2014) 134:1527–34. doi: 10.1038/jid.2013.446
2. Augustin M, Herberger K, Hintzen S, Heigel H, Franzke N, Schäfer I. Prevalence of skin lesions and need for treatment in a cohort of 90 880 workers. Br J Dermatol. (2011) 165:865–73. doi: 10.1111/j.1365-2133.2011.10436.x
3. Bewley A, Affleck A, Bundy C, Higgins E, McBride S. Psychodermatology services guidance: The report of the British Association of Dermatologists’ Psychodermatology Working Party. Br J Dermatol. (2013) 168:1149–50. doi: 10.1111/bjd.12330
4. Herbst I, Jemec G. Body dysmorphic disorder in dermatology: A systematic review. Psychiatr Q. (2020) 91:1003–10. doi: 10.1007/s11126-020-09757-y
5. Rook A, Wilkinson D. Psychocutaneous disorders. 1st ed. In: Burns T, Breathnach S editors. Textbook of Dermatology. Oxford: Blackwell Scientific Publications (1979). p. 2023–35.
6. Schneider G, Gieler U. [Psychosomatic dermatology - state of the art]. Z Psychosom Med Psychother. (2001) 47:307–31. doi: 10.13109/zptm.2001.47.4.307
7. Kellett S, Gilbert P. Acne: A biopsychosocial and evolutionary perspective with a focus on shame. Br J Health Psychol. (2001) 6(Pt 1):1–24. doi: 10.1348/135910701169025
8. Zhang H, Wang M, Zhao X, Wang Y, Chen X, Su J. Role of stress in skin diseases: A neuroendocrine-immune interaction view. Brain Behav Immun. (2024) 116:286–302. doi: 10.1016/j.bbi.2023.12.005
9. Davey G. Self-reported fears to common indigenous animals in an adult UK population: The role of disgust sensitivity. Br J Psychol. (1994) 85(Pt 4):541–54. doi: 10.1111/j.2044-8295.1994.tb02540.x
10. Oaten M, Stevenson R, Case T. Disgust as a disease-avoidance mechanism. Psychol Bull. (2009) 135:303–21. doi: 10.1037/a0014823
11. Powell P, Simpson J, Overton P. An Introduction to the Revolting Self: Self-Disgust as an Emotion Schema. In: Powell P, Overton P, Simpson J editors. The Revolting Self. London: Routledge (2018). p. 1–24.
12. Sedighimornani N. Shame and its features: Understanding of shame. Eur J Soc Sci. (2018) 3:1453426. doi: 10.5281/zenodo.1453426
13. Gilbert P. What is shame? Some core issues and controversies. In: Gilbert P, Andrews B editors. Shame: Interpersonal Behavior, Psychopathology, and Culture. New York, NY: Oxford University Press (1998). p. 3–38.
14. Tangney J. The self- conscious emotions: Shame, guilt, embarrassment and pride. In: B Ellis editor. The Philosophy of Nature: A Guide to the New Essentialism. London: Routledge (2014). p. 541–68.
15. Tangney J, Miller R, Flicker L, Barlow D. Are shame, guilt, and embarrassment distinct emotions? J Pers Soc Psychol. (1996) 70:1256–69. doi: 10.1037//0022-3514.70.6.1256
16. Keltner D. Evidence for the distinctness of embarrassment, shame, and guilt: A study of recalled antecedents and facial expressions of emotion. Cognit Emot. (1996) 10:155–72. doi: 10.1080/026999396380312
17. Magin P, Adams J, Heading G, Pond D, Smith W. The psychological sequelae of psoriasis: Results of a qualitative study. Psychol Health Med. (2009) 14:150–61. doi: 10.1080/13548500802512294
18. Germain N, Augustin M, François C, Legau K, Bogoeva N, Desroches M, et al. Stigma in visible skin diseases - a literature review and development of a conceptual model. J Eur Acad Dermatol Venereol. (2021) 35:1493–504. doi: 10.1111/jdv.17110
19. Loughlin M, Dolezal L, Hutchinson P, Subramani S, Milani R, Lafarge C. Philosophy and the clinic: Stigma, respect and shame. J Eval Clin Pract. (2022) 28:705–10. doi: 10.1111/jep.13755
20. Luoma J, Kohlenberg B, Hayes S, Bunting K, Rye A. Reducing self-stigma in substance abuse through acceptance and commitment therapy: Model, manual development, and pilot outcomes. Addict Res Theory. (2008) 16:149–65. doi: 10.1080/16066350701850295
21. Stynes G, Leão C, McHugh L. Exploring the effectiveness of mindfulness-based and third wave interventions in addressing self-stigma, shame and their impacts on psychosocial functioning: A systematic review. J Context Behav Sci. (2022) 23:174–89. doi: 10.1016/j.jcbs.2022.01.006
22. Luck-Sikorski C, Roßmann P, Topp J, Augustin M, Sommer R, Weinberger N. Assessment of stigma related to visible skin diseases: A systematic review and evaluation of patient-reported outcome measures. J Eur Acad Dermatol Venereol. (2022) 36:499–525. doi: 10.1111/jdv.17833
23. Lange S, Zschocke I, Langhardt S, Amon U, Augustin M. [Effects of combined dermatological and behavioural medicine therapy in hospitalized patients with psoriasis and atopic dermatitis]. Hautarzt. (1999) 50:791–7. doi: 10.1007/s001050050986
24. Taube K, Seikowski K. Psychodermatologie. Akt Dermatol. (2014) 40:363–71. doi: 10.1055/s-0034-1377481
25. de Zoysa P. Psychological interventions in dermatology. Indian J Dermatol. (2013) 58:56–60. doi: 10.4103/0019-5154.105312
27. Neff K. Self-compassion: An alternative conceptualization of a healthy attitude toward oneself. Self Identity. (2003) 2:85–101. doi: 10.1080/15298860390129863
28. Gilbert P. An introduction to compassion focused therapy in cognitive behavior therapy. Int J Cogn Ther. (2010) 3:97–112. doi: 10.1521/ijct.2010.3.2.97
29. Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS Med. (2021) 18:e1003583. doi: 10.1371/journal.pmed.1003583
30. Bartholomew E, Chung M, Yeroushalmi S, Hakimi M, Bhutani T, Liao W. Mindfulness and meditation for psoriasis: A systematic review. Dermatol Ther. (2022) 12:2273–83. doi: 10.1007/s13555-022-00802-1
31. Meneo D, Martoni M, Giannandrea A, Tengattini V, Baglioni C. Mindfulness and self-compassion in dermatological conditions: A systematic narrative review. Psychol Health. (2024) 39:268–300. doi: 10.1080/08870446.2022.2070619
32. Lahousen T, Kupfer J, Gieler U, Hofer A, Linder M, Schut C. Differences between psoriasis patients and skin-healthy controls concerning appraisal of touching, shame and disgust. Acta Derm Venereol. (2016) 96:78–82. doi: 10.2340/00015555-2373
33. Armstrong A, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: Findings from the National Psoriasis Foundation survey data 2003-2011. PLoS One. (2012) 7:e52935. doi: 10.1371/journal.pone.0052935
34. Augustin M, Radtke M. Quality of life in psoriasis patients. Expert Rev Pharmacoecon Outcomes Res. (2014) 14:559–68. doi: 10.1586/14737167.2014.914437
35. Łakuta P, Marcinkiewicz K, Bergler-Czop B, Brzezińska-Wcisło L, Słomian A. Associations between site of skin lesions and depression, social anxiety, body-related emotions and feelings of stigmatization in psoriasis patients. Postepy Dermatol Alergol. (2018) 35:60–6. doi: 10.5114/pdia.2016.62287
36. Ong K, Sun M, Rieder E. Behavioral modification for acne excoriée and skin picking. In: Rieder E, Fried R editors. Essential Psychiatry for the Aesthetic Practitioner. Hoboken, NJ: Wiley (2021). p. 216–22.
37. Ginsburg I, Link B. Psychosocial consequences of rejection and stigma feelings in psoriasis patients. Int J Dermatol. (1993) 32:587–91. doi: 10.1111/j.1365-4362.1993.tb05031.x
38. Ginsburg I, Link B. Feelings of stigmatization in patients with psoriasis. J Am Acad Dermatol. (1989) 20:53–63. doi: 10.1016/s0190-9622(89)70007-4
39. Wabnegger A, Übel S, Suchar G, Schienle A. Increased emotional reactivity to affective pictures in patients with skin-picking disorder: Evidence from functional magnetic resonance imaging. Behav Brain Res. (2018) 336:151–5. doi: 10.1016/j.bbr.2017.08.040
40. van Beugen S, Maas J, van Laarhoven A, Galesloot T, Rinck M, Becker E, et al. Implicit stigmatization-related biases in individuals with skin conditions and their significant others. Health Psychol. (2016) 35:861–5. doi: 10.1037/hea0000404
41. National Heart, Lung, and Blood Institute. Study Quality Assessment Tools. (2013). Available online at: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools (accessed July 9, 2021).
42. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): A 32-item checklist for interviews and focus groups. Int J Qual Health Care. (2007) 19:349–57. doi: 10.1093/intqhc/mzm042
43. Russo P, Ilchef R, Cooper A. Psychiatric morbidity in psoriasis: A review. Aust J Dermatol. (2004) 45:155–9; quiz 160–1. doi: 10.1111/j.1440-0960.2004.00078.x.
44. Rzepa T, Jakubowicz O, Witmanowski H, Zaba R. Disease-induced level of shame in patients with acne, psoriasis and syphilis. Postepy Dermatol Alergol. (2013) 30:233–6. doi: 10.5114/pdia.2013.37033
45. Sampogna F, Tabolli S, Abeni D. Living with psoriasis: Prevalence of shame, anger, worry, and problems in daily activities and social life. Acta Derm Venereol. (2012) 92:299–303. doi: 10.2340/00015555-1273
46. Ständer S, Steinke S, Augustin M, Metze D, Loser K, Baeumer D, et al. Quality of life in psoriasis vulgaris: Use of the ItchyQoL question-naire in a secukinumab phase III trial in patients with psoriasis vulgaris. Acta Derm Venereol. (2019) 99:1085–90. doi: 10.2340/00015555-3275
47. Homayoon D, Hiebler-Ragger M, Zenker M, Weger W, Unterrainer H, Aberer E. Relationship between skin shame, psychological distress and quality of life in patients with psoriasis: A pilot study. Acta Derm Venereol. (2020) 100:adv00205. doi: 10.2340/00015555-3563
48. Coates L, Orbai A, Azevedo V, Cappelleri J, Steinberg K, Lippe R, et al. Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire. Health Qual Life Outcomes. (2020) 18:173. doi: 10.1186/s12955-020-01422-z
49. Aberer E, Hiebler-Ragger M, Zenker M, Weger W, Hofer A, Unterrainer H. Facets of shame are differently expressed in dermatological disease: A prospective observational study. Br J Dermatol. (2020) 183:169–71. doi: 10.1111/bjd.18899
50. Jankowiak B, Kowalewska B, Krajewska-Kułak E, Khvorik D. Stigmatization and quality of life in patients with psoriasis. Dermatol Ther. (2020) 10:285–96. doi: 10.1007/s13555-020-00363-1
51. Torales J, Echeverría C, Barrios I, García O, O’Higgins M, Castaldelli-Maia J, et al. Psychodermatological mechanisms of psoriasis. Dermatol Ther. (2020) 33:e13827. doi: 10.1111/dth.13827
52. Hayashi N, Higaki Y, Kawamoto K, Kamo T, Shimizu S, Kawashima M. A cross-sectional analysis of quality of life in Japanese acne patients using the Japanese version of Skindex-16. J Dermatol. (2004) 31:971–6. doi: 10.1111/j.1346-8138.2004.tb00639.x
53. Tan J, Beissert S, Cook-Bolden F, Chavda R, Harper J, Hebert A, et al. Impact of facial atrophic acne scars on quality of life: A multi-country population-based survey. Am J Clin Dermatol. (2022) 23:115–23. doi: 10.1007/s40257-021-00628-1
54. Kouris A, Platsidaki E, Kouskoukis C, Christodoulou C. Psychological parameters of psoriasis. Psychiatriki. (2017) 28:54–9. doi: 10.22365/jpsych.2017.281.54
55. Jafferany M, Pastolero P. Psychiatric and psychological impact of chronic skin disease. Prim Care Companion CNS Disord. (2018) 20:17nr02247. doi: 10.4088/PCC.17nr02247
56. Hazarika N, Archana M. The psychosocial impact of acne vulgaris. Indian J Dermatol. (2016) 61:515–20. doi: 10.4103/0019-5154.190102
57. Tan J, Beissert S, Cook-Bolden F, Chavda R, Harper J, Hebert A, et al. Evaluation of psychological well-being and social impact of atrophic acne scarring: A multinational, mixed-methods study. JAAD Int. (2022) 6:43–50. doi: 10.1016/j.jdin.2021.11.006
58. Gochnauer H, Valdes-Rodriguez R, Cardwell L, Anolik R. The psychosocial impact of atopic dermatitis. Adv Exp Med Biol. (2017) 1027:57–69. doi: 10.1007/978-3-319-64804-0_6
59. Ngaage M, Agius M. The psychology of scars: A mini-review. Psychiatr Danub. (2018) 30(Suppl 7):633–8.
60. O’Neill J, Chan Y, Rapp S, Yosipovitch G. Differences in itch characteristics between psoriasis and atopic dermatitis patients: Results of a web-based questionnaire. Acta Derm Venereol. (2011) 91:537–40. doi: 10.2340/00015555-1126
61. Barisone M, Bagnasco A, Hayter M, Rossi S, Aleo G, Zanini M, et al. Dermatological diseases, sexuality and intimate relationships: A qualitative meta-synthesis. J Clin Nurs. (2020) 29:3136–53. doi: 10.1111/jocn.15375
62. Fisher S, Ellen M, Cohen A, Kagan I. Coping with psoriasis or hidradenitis suppurativa: A qualitative study. Adv Skin Wound Care. (2020) 33:662–8. doi: 10.1097/01.ASW.0000720260.58886.08
63. Almeida V, Leite Â, Constante D, Correia R, Almeida I, Teixeira M, et al. The mediator role of body image-related cognitive fusion in the relationship between disease severity perception, acceptance and psoriasis disability. Behav Sci. (2020) 10:142. doi: 10.3390/bs10090142
64. Shah R, Bewley A. Psoriasis: ‘the badge of shame’. A case report of a psychological intervention to reduce and potentially clear chronic skin disease. Clin Exp Dermatol. (2014) 39:600–3. doi: 10.1111/ced.12339
65. Wojciechowska-Zdrojowy M, Reid A, Szepietowski J, Wojciechowski A. Analysis of sexual problems in men with psoriasis. J Sex Marital Ther. (2018) 44:737–45. doi: 10.1080/0092623X.2018.1462276
66. Ramsay B, O’Reagan M. A survey of the social and psychological effects of psoriasis. Br J Dermatol. (1988) 118:195–201. doi: 10.1111/j.1365-2133.1988.tb01774.x
67. Hrehorów E, Salomon J, Matusiak L, Reich A, Szepietowski J. Patients with psoriasis feel stigmatized. Acta Derm Venereol. (2012) 92:67–72. doi: 10.2340/00015555-1193
68. Magin P, Adams J, Heading G, Pond D, Smith W. Experiences of appearance-related teasing and bullying in skin diseases and their psychological sequelae: Results of a qualitative study. Scand J Caring Sci. (2008) 22:430–6. doi: 10.1111/j.1471-6712.2007.00547.x
69. Schielein M, Tizek L, Schuster B, Ziehfreund S, Biedermann T, Zink A. Genital psoriasis and associated factors of sexual avoidance - a people-centered cross-sectional study in Germany. Acta Derm Venereol. (2020) 100:adv00151. doi: 10.2340/00015555-3509
70. Buckwalter K. The influence of skin disorders on sexual expression. Sex Disabil. (1982) 5:98–106. doi: 10.1007/BF01103301
71. Vladut C, Kállay É. Psychosocial implications of psoriasis: Theoretical review. Cogn Brain Behav. (2010) 14:23–35.
72. George C, Sutcliffe S, Scheinmann D, Mizara A, McBride S. Psoriasis: The Skin I’m In. Development of a behaviour change tool to improve the care and lives of people with psoriasis. Clin Exp Dermatol. (2021) 46:888–95. doi: 10.1111/ced.14594
73. Mento C, Rizzo A, Muscatello M, Zoccali R, Bruno A. Negative emotions in skin disorders: A systematic review. Int J Psychol Res. (2020) 13:71–86. doi: 10.21500/20112084.4078
74. Wahl A, Gjengedal E, Hanestad B. The bodily suffering of living with severe psoriasis: In-depth interviews with 22 hospitalized patients with psoriasis. Qual Health Res. (2002) 12:250–61. doi: 10.1177/104973202129119874
75. Narayanan S, Guyatt V, Franceschetti A, Hautamaki E. Disease burden and patient reported outcomes among patients with moderate to severe psoriasis: An ethnography study. Psoriasis. (2015) 5:1–7. doi: 10.2147/PTT.S74906
76. Schienle A, Wabnegger A. Self-disgust in patients with dermatological diseases. Int J Behav Med. (2022) 29:827–32. doi: 10.1007/s12529-022-10058-w
77. Kleyn C, McKie S, Ross A, Montaldi D, Gregory L, Elliott R, et al. Diminished neural and cognitive responses to facial expressions of disgust in patients with psoriasis: A functional magnetic resonance imaging study. J Invest Dermatol. (2009) 129:2613–9. doi: 10.1038/jid.2009.152
78. Kelly A, Zuroff D, Shapira L. Soothing oneself and resisting self-attacks: The treatment of two intrapersonal deficits in depression vulnerability. Cogn Ther Res. (2009) 33:301–13. doi: 10.1007/s10608-008-9202-1
79. Krasuska M, Millings A, Lavda A, Thompson A. Compassion-focused self-help for skin conditions in individuals with insecure attachment: A pilot evaluation of acceptability and potential effectiveness. Br J Dermatol. (2018) 178:e122–3. doi: 10.1111/bjd.15934
80. Muftin Z, Gilbert P, Thompson A. A randomized controlled feasibility trial of online compassion-focused self-help for psoriasis. Br J Dermatol. (2022) 186:955–62. doi: 10.1111/bjd.21020
81. Hiebler-Ragger M, Unterrainer H, Thompson A, Kellett S, Aberer E. [German version of the Skin Shame Scale (SSS-24) : Validation with dermatological patients and dermatologically healthy individuals]. Hautarzt. (2020) 71:124–9. doi: 10.1007/s00105-019-04501-5
82. Scheel C, Bender C, Tuschen-Caffier B, Jacob G. SHAME–Entwicklung eines Fragebogens zur Erfassung positiver und negativer Aspekte von Scham. Z Klin Psychol Psychother. (2013) 42:280–90. doi: 10.1026/1616-3443/a000228
83. Gillanders D, Bolderston H, Bond F, Dempster M, Flaxman P, Campbell L, et al. The development and initial validation of the cognitive fusion questionnaire. Behav Ther. (2014) 45:83–101. doi: 10.1016/j.beth.2013.09.001
84. Neff K. The development and validation of a scale to measure self-compassion. Self Identity. (2003) 2:223–50. doi: 10.1080/15298860309027
85. Gossec L, de Wit M, Kiltz U, Braun J, Kalyoncu U, Scrivo R, et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: Elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis. (2014) 73:1012–9. doi: 10.1136/annrheumdis-2014-205207
86. Finlay A, Khan G. Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. (1994) 19:210–6. doi: 10.1111/j.1365-2230.1994.tb01167.x
87. Chren M, Lasek R, Sahay A, Sands L. Measurement properties of Skindex-16: A brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg. (2001) 5:105–10. doi: 10.1007/BF02737863
88. Lu Y, Duller P, van der Valk P, Evers A. Helplessness as predictor of perceived stigmatization in patients with psoriasis and atopic dermatitis. Dermatol Psychosom. (2003) 4:146–50. doi: 10.1159/000073991
89. Schut C, Linder D, Brosig B, Niemeier V, Ermler C, Madejski K, et al. Appraisal of touching behavior, shame and disgust: A cross-cultural-study. Int J Cult Ment Health. (2013) 6:1–15. doi: 10.1080/17542863.2011.602530
90. Chren M, Lasek R, Flocke S, Zyzanski S. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. (1997) 133:1433–40. doi: 10.1001/archderm.1997.03890470111018
91. Krause K, Kessler B, Weller K, Veidt J, Chen S, Martus P, et al. German version of ItchyQoL: Validation and initial clinical findings. Acta Derm Venereol. (2013) 93:562–8. doi: 10.2340/00015555-1544
92. Oosthuizen P, Lambert T, Castle D. Dysmorphic concern: Prevalence and associations with clinical variables. Aust N Z J Psychiatry. (1998) 32:129–32. doi: 10.3109/00048679809062719
93. Layton A, Dréno B, Finlay A, Thiboutot D, Kang S, Lozada V, et al. New patient-oriented tools for assessing atrophic acne scarring. Dermatol Ther. (2016) 6:219–33. doi: 10.1007/s13555-016-0098-5
94. Schienle A, Ille R, Sommer M, Arendasy M. Diagnostik von Selbstekel im Rahmen der Depression. Verhaltenstherapie. (2014) 24:15–20. doi: 10.1159/000360189
95. Andrews B, Qian M, Valentine J. Predicting depressive symptoms with a new measure of shame: The Experience of Shame Scale. Br J Clin Psychol. (2002) 41(Pt 1):29–42. doi: 10.1348/014466502163778
96. Goss K, Gilbert P, Allan S. An exploration of shame measures—I: The other as shamer scale. Pers Individ Differ. (1994) 17:713–7. doi: 10.1016/0191-8869(94)90149-X
97. Baião R, Gilbert P, McEwan K, Carvalho S. Forms of self-criticising/attacking & self-reassuring scale: Psychometric properties and normative study. Psychol Psychother. (2015) 88:438–52. doi: 10.1111/papt.12049
Keywords: acne, compassion, disgust, psoriasis, shame, atopic eczema
Citation: Fink-Lamotte J, Wehle S, Brinkmann F, Pelzer M, Exner C and Stierle C (2025) Shame and disgust in patients with inflammatory skin diseases: a systematic review of psychological correlates and psychotherapeutic approaches. Front. Med. 12:1620940. doi: 10.3389/fmed.2025.1620940
Received: 30 April 2025; Accepted: 04 June 2025;
Published: 30 June 2025.
Edited by:
Sebastian Yu, Kaohsiung Medical University, TaiwanReviewed by:
Carsten Spitzer, University Hospital Rostock, GermanyChong Seng Choi, Universiti Putra Malaysia, Malaysia
Copyright © 2025 Fink-Lamotte, Wehle, Brinkmann, Pelzer, Exner and Stierle. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jakob Fink-Lamotte, amFrb2IuZmluay1sYW1vdHRlQHVuaS1wb3RzZGFtLmRl
†ORCID: Jakob Fink-Lamotte, orcid.org/0000-0002-4384-4903